Pharmacotherapy of autistic spectrum disorders in children: the experience of foreign psychopharmacologists
Suggested citation:
Borodina LG. [Pharmacotherapy of autistic spectrum disorders in children: the experience of foreign psychopharmacologists]. Rossiiskii psikhiatricheskii zhurnal [Russian Journal of Psychiatry]. 2013;(1):60-70. Russian
This review presents recent findings from foreign research on pharmacotherapy of autism spectrum disorders (ASD). Highlighted are various indicators of both the efficacy of traditional groups of psychotropic agents and bold attempts at using other medicinal product groups (hormones, immunomodulatory drugs, cholinesterase inhibitors) and individual medications with recently discovered antiautistic properties such as cyproheptadine, fagotidine and others. Each section is provided with a short theoretical background on medicinal products group and how it relates to clinical picture or neurophysiology of ASD. Special emphasis is attached to the possibility of the effect of drugs on the basic (nuclear) autistic symptomatology. Data are adduced from foreign reviews with medications graded according to their efficacy, methodological validity and the possibility of analyzing the conducted research and prospective viability of future trends in the scientific quest.
1. Башина В.М., Симашкова Н.В. Аутизм в детстве // Лечение и реабилитация. - М.: Медицина, 1999. - С. 171-206. 2. Брин И.Л., Дунайкин М.Л., Шейнкман О.Г. Элькар в комплексной терапии нарушений нервно-психического развития детей с последствиями перинатальных поражений мозга // Вопр. соврем. педиатрии. - 2005, Т. 4, № 1. 3. Козловская Г.В., Калинина М.А., Горюнова А.В., и др. Опыт применения рисполепта при лечении раннего детского аутизма и шизофрении у детей // Психиатрия и психофармакотер. - 2000. - Т. 1, № 2. - Прил. 4. Симашкова Н.В. Эффективная фармакотерапия и реабилитация больных с расстройствами аутистического спектра // Неврология и психиатрия. - 2011. - № 3. - С. 14-22. 5. Anagnostou E., Hansen R.L. Medical treatment overview: traditional and novel psychopharmacological and complementary and alternative medications // Curr. Opin. Pediatr. - 2011. - Vol. 23 (6). - P. 621-627. 6. Andari E., Duhamel J.R. Zolla T. et al. Promoting social behavior with oxytocin in high functioning autism spectrum disorder // Proc. Natl Acad. Sci. USA. - 2010. - Vol. 107 (9). - P. 4389- 4394. 7. Anderson L.T., Campbell M., Adams P. et al. The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children // J. Autism Dev. Disord. - 1989. - Vol. 19 (2). - P. 2 2 7- 2 3 9 . 8. Baghdadli A., Gounier V., Aussilloux G. Review of psychopharmacological treatments in adolescents and adults with autistic disorders // Encephale. - 2002. - Vol. 28 (3 Pt 1). - P. 24 8 - 2 5 4. 9. Banaschewski T., Poustka L., Holtmann M. Autism and ADHD across the life span. Differential diagnoses or comordidity? // Nervenarzt. - 2011. - Vol. 82 (5). - P. 573-580. 10. Barnard L., Young A.H., Pearson J. et al. A systematic review of the use of atypical antipsychotics in autism // J. Psychopharmacol. - 2002. - Vol. 16 (1). - P. 93-101. 11. Bradstreet J.J., Smith S., Granpeesheh D. et al. Spironolactone might be a desirable immunologic and hormonal intervention in autism spectrum disorders // Med. Hypotheses. - 2007. - Vol. 68 (5). - P. 979-987. 12. Branford D., Bhaumik S., Naik B. Selective serotonin re-uptake inhibitors for the treatment of perseverative and maladaptive behaviors of people with intellectual disability // J. Intellect. Disabil. Res. - 1998. - Vol. 42 (Pt 40). - P. 301-306. 13. Chabrol H., Bonnet D., Roge B. Psychopharmacology of autism // Encephale. - 1996 May-June. - Vol. 22 (3). - P. 197-203. 14. Chanizadeh A. Atomoxetine for Treating ADHD symptoms in Autism: a Systematic Review // J. Atten. Disord. - 2012. - Apr. 27 (Epub ahead of print). 15. Charnsil C. Efficacy of atomoxetine in children with severe autistic disorders and symptoms of ADHD: an open-label study // J. Atten Disord. - 2011. - Vol. 15 (8). - P. 684-689. 16. Chez M.G., Guido-Estrada N. Immune therapy in autism: historical experience and future directions with immunomodulatory therapy // Neurotheraputics. - 2010. - Vol. 7 (3). - P. 2 9 3 - 3 0 1. 17. Coo H., Quellette-Kuntz H., Lloyd J.E. et al. Trends in autism prevalence: diagnostic substitution revisited // J. Autism Dev. Disord. - 2008. - Vol. 38 (6). - P. 1036-1046. 18. DeLong G.R., Ritch C.R., Busch S. Fluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievement // Dev. Med. Child Neurol. - 2002. - Vol. 44 (10). - P. 652-659. 19. Dollfus S., Petit M., Menard J.F. et al. Amisulpride versus bromocriptine in infantile autism: a controlled crossover comparative study of two drugs with opposite effects on dopaminergic function // J. Autism Dev. Disord. - 1992. - Vol. 22 (1). - P. 47-60. 20. Elbe D., Lalani Z. Review of the pharmacotherapy of irritability of autism // J. Can. Acad. Child Adolesc. Psychiatry. - 2012. - Vol. 21 (2). - P. 130-146. 21. Fink H., Taylor M.A., Chaziuddin N. Catatonia in autistic spectrum disorders: a medical treatment algorithm // Int. Rev. Neurobiol. - 2006. - Vol. 72. - P. 233-244. 22. Frye R.E., Huffman L.C., Elliott G.R. Tetrahydrobiopterin as a novel therapeutic intervention for autism // Neurotheraputics. - 2010. - Vol. 7 (3). - P. 241-249. 23. Frye R.E., Sreenivasula S., Adams J.B. Traditional and nontraditional treatments for autism spectrum disorders with seizures: an on-line survey // BMC Pediatr. - 2011. - Vol. 18. - P. 11- 3 7. 24. Garcia-Penas J.J. Antiepileptic drugs in the treatment of autistic regression syndrome // Rev. Neurol. - 2005. - Vol. 40, suppl. 1. - P. s173-s176. 25. Goiness P., Van de Water J. The immune system’s role in the biology of autism // Curr. Opin. Neurol. - 2010. - Vol. 23 (2). - P. 111-117. 26. Gralton E.J., james D.H., Lindsey M.P. Antipsychotic medication, psychiatric diagnosis and children with intellectual disability // J. Intellect. Disabil. Res. - 1998. - Vol. 42 (Pt 1). - P. 4 9 - 5 7. 27. Green J.J., Hollander E. Autism and oxytocin: new developments in translational approaches to therapeutics // Neurotheraputics. - 2010. - Vol. 7 (3). - P. 250-257. 28. Guastella A.J., Einfeld S.L., Gray R.M. et al. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorder // Biol. Psychiatry. - 2010. - Vol. 67 (7). - P. 692-694. 29. Hjiej H., Doyen C., Couprie C., Kaye K. et al. Substitutive and dietic approaches in childhood autistic disorder: interests and limits // Encephale. - 2008. - Vol. 34 (5). - P. 496-503. 30. Hollander E., Chaplin W., Soorya L. et al. Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders // Neuropsychopharmacology. - 2010. - Vol. 35 (4). - P. 990-998. 31. Huffman L.S., Sutcliffe T.L., Tanner I.S. et al. Management of symptoms in children with autism spectrum disorders: a comprehensive review of pharmacologic and complementary - alternative medicine treatments // J. Dev. Behav. Pediatr. - 2011. - Vol. 32 (1). - P. 56-68. 32. James S., Montgomery P., Williams K. Omega-3 fatty acids supplementation for autism spectrum disorders (ASD) // Cochrane Database Syst. Rev. - 2011 Nov. 9; (11): CD 007992. 33. Janusonis S. Origin of the blood hyperserotoninemia of autism // Theor. Biol. Med. Model. - 2008. - Vol. 3 (1). - P. 3 5 5 - 3 6 2 . 34. Jorgensen O.S. Psychopharmacological treatment of psychotic children. A survey // Acta Psychiatr. Scand. - 1979. - Vol. 59 (2). - P. 229-238. 35. Kakooza-Mwesige A., Wachtel L.E., Dhosshe D.M. Catatonia in autism: implications across the life span // Eur. Child Adolesc. Psychiatry. - 2008. - Vol. 17 (6). - P. 327-335. 36. Kaplan G., McCracken J.T. Psychopharmacology of autism spectrum disorders // Pediatr. Clin. North Am. - 2012. - Vol. 59. - P. 17 5 -18 7. 37. King C.R. A novel embryological theory of autism causation involving endogenous biochemicals capable of initiating cellular gene transcription: a possible link between twelve autism risk factors and the autism "epidemic" // Med. Hypotheses. - 2011. - Vol. 76 (5). - P. 653-660. 38. Krishnaswami S., McPheeters M.L., Veenstra-Vanderweele J. A systematic review of secretin for children with autism spectrum disorders // Pediatrics. - 2011. - Vol. 127 (5). - P. e1322-e1325. 39. Leventhal B.L., Cook E.V. Jr, Morford M. et al. Clinical and neurochemical effects of fenfluramine in children with autism // J. Neuropsychiatry Clin. Neurosci. - 1993. - Vol. 5 (3). - P. 307-315. 40. Linday L.A. Oral famotidine: a potential treatment for children with autism // Med. Hypotheses. - 1997. - Vol. 48 (5). - P. 381-386. 41. Linday L.A., Tsiouris J.A., Cohen I.L. et al. Famotidine treatment for children with autistic spectrum disorders: pilot research using single subject research design // J. Neurol. Transm. - 2001. - Vol. 108 (5). - P. 593-611. 42. Luby J., Mrakotsky C., Stalets M.M. et al. Risperidone in preschool children with autism spectrum disorders: an investigation of safety and efficacy // J. Child Adolesc. Psychopharmacol. - 2006. - Vol. 16 (5). - P. 575-587. 43. Marrosu F., Marrozu G., Rachel M.G. et al. Paradoxical reactions elicited by diazepam in children with classic autism // Funct. Neurol. - 1987 Jul-Sep. - Vol. 2(3). - P. 355-361. 44. Matarazzo E.B. Treatment of late onset autism as a consequence of probable autoimmune processes related to chronic bacterial infection // World J. Biol. Psychiatry. - 2002. - Vol. 3 (3). - P. 162-166. 45. McCracken J.T. Safety issues with drug therapies for autism spectrum disorder // J. Clin. Psychiatry. - 2005. - Vol. 66, suppl. 10. - P. 32-37. 46. McDougle C.L., Brodkin E.S., Naylor S.T. et al. Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation // J. Clin. Psychopharmacol. - 1998. - Vol. 18 (1). - P. 62-66. 47. McDougle C.L., Kresch L.E., Posey D.G. Repetetive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors // J. Autism Dev. Disord. - 2000 Oct. - Vol. 30 (5). - P. 427-435. 48. McDougle C.L., Kem D.L., Posey D.G. Case series: use of ziprasidone for maladaptive symptoms in youth with autism // J. Am. Acad. Child Adolesc. Psychiatry. - 2002. - Vol. 41 (8). - P. 921-927. 49. McKinney C., Renk K. Atypical antipsychotic medications in the management of disruptive behaviors in children: safety guidelines and recommendations // Clin. Psychol. Rev. - 2011. - Vol. 31 (3). - P. 465-471. 50. McPheeters M.L., Warren Z., Sathe N. A systematic review of medical treatments for children with autism spectrum disorders // Pediatrics. - 2011. - Vol. 127, N 5. - P. e1312-e1321. 51. Millward C., Ferriter M., Calver S. et al. Gluten- and casein-free diet for autistic spectrum disorders // Cochrane Database Syst. Rev. - 2008. - Vol. 16 (2): CD 003498. 52. Ming X., Julu P.O., Brimacombe M. et al. Reduced cardiac parasympathetic activity in children with autism // Brain Dev. - 2005. - Vol. 5. - P. 486-493. 53. Modi M.E., Young L.J. The oxytocin system in drug discovery for autism: animal models and novel therapeutic strategies // Horm. Behav. - 2012. - Vol. 61 (3). - P. 340-350. 54. Moscal J.R., Burqdorf J. A novel NMDA receptor glycine-syte partial agonist GLYX-13 has therapeutic potential for the treatment of autism // Neurosci. Biobehav. Rev. - 2011. - Vol. 35 (9). - P. 19 8 2 -19 8 8 . 55. Newcomer J.W. Second-generation (atypical) antipsycotics and metabolic effects: a comprehensive literature review // CNS Drugs. - 2005. - Vol. 19, suppl. 1. - P. 1-93. 56. Niederhofer H., Staffen W., Mair A. Galantamine might be effective in treating autistic disorder // BMJ. - 2002. - Vol. 325 (7377). - P. 1422. 57. Posey D.J., Walsh K.H., Wilson G.A. et al. Risperidone in the treatment of two very young children with autism // J. Child Adolesc. Psychopharmacol. - 1999. - Vol. 9 (4). - P. 273-276. 58. Posey D.J., McDougle C.J. The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders // Harv. Pev. Psychiatry. - 2000. - Vol. 8 (2). - P. 45-63. 59. Posey D.J., Puntney J.I., Sasher T.M. et al. Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases // J. Child Adolesc. Psychopharmacol. - 2004. - Vol. 14 (2). - P. 2 3 3 - 241. 60. Posey D.J., Erickson C.A., McDougle C.J. Developing drugs for core social and communication impairment in autism // Child Adolesc. Psychiatr Clin. N. Am. - 2008. - Vol. 17 (4). - P. 7 8 7. 61. Poustka L., Banaschewski T., Poustka F. Psychopharmacology of autism spectrum disorders // Nervenarzt. - 2011. - Vol. 82 (5). - P. 582-589. 62. Rajapakse T., Pringsheim T. Pharmacotheraputics of Tourette syndrome and stereotypes in autism // Semin. Pediatr. Neurol. - 2010. - Vol. 17 (4). - P. 254-260. 63. Realmuto G.M., August G.J., Garfinkel B.D. Clinical effect of buspirone in autistic children // J. Clin. Psychopharmacol. - 1989. - Vol. 9 (2). - P. 122-125. 64. Robb A.S. Managing irritability and aggression in autism spectrum disorders in children and adolescents // Dev. Disabil. Res. Rev. - 2010. - Vol. 16 (3). - P. 258-264. 65. Rossignol D.A. Novel and emerging treatments for autism spectrum disorder: a systematic review // Ann. Clin. Psychiatry. - 2009. - Vol. 21 (4). - P. 213-236. 66. Rossignol D.A., Frye R.E. Melatonin in autism spectrum disorders: a systematic review and meta-analysis // Dev. Med. Child Neurol. - 2011. - Vol. 53 (9). - P. 783-792. 67. Rossignol D.A., Frye R.E. Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis // Mol. Psychiatry. - 2012. - Vol. 17 (3). - P. 290-314. 68. Rothenberger A. Psychopharmacological treatment of self-injurious behavior in individuals with autism // Acta Paedopsychiatr. - 1993. - Vol. 56 (2). - P. 99-103. 69. Rugino T.A., Samsock T.C. Levetiracetam in autistic children: an open-label study // J. Dev. Behav. Pediatr. - 2002. - Vol. 23 (4). - P. 22-30. 70. Shattock P., Whiteley P. Biochemical aspects in autism spectrum disorders: updating the opioid-excess theory and presenting new opportunities for biomedical intervention // Expert Opin. Theor. Targets. - 2002. - Vol. 6 (2). - P. 175-183. 71. Sloman L. Use of medication in pervasive developmental disorders // Psychiatr. Clin. North Am. - 1991. - Vol. 14 (1). - P. 16 5 -18 2 . 72. Stachnik J.M., Nunn-Thompson C. Use of atypical antipsychotics in the treatment of autistic disorder // Ann. Pharmacother. - 2007. - Vol. 41 (4). - P. 626-634. 73. Wei H., Dobkin C., Sheikh F.M. et al. the therapeutic effect of memantine through the stimulanion of synapse formation and dendritic spine maturation in autism and fragile X syndrome // PLoS One. - 2012. - Vol. 7 (5). - P. e 36981. 74. White S.W., Oswald D., Ollendick T. et al. Anxiety in children and adolescents with autism spectrum disorders // Clin. Psychol. Rev. - 2009. - Vol. 29 (3). - P. 216-229. 75. Zuddas A., Di Martino A., Muglia P. et al. Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation // J. Child Adolesc. Psychopharmacol. - 2000. - Vol. 10 (2). - P. 79-90.
DOI: http://dx.doi.org/10.24411/1560-957X-2013-11311
Article Metrics
Metrics powered by PLOS ALM